Hansson Mattias, Madsen Ole D
Hagedorn Research Institute, Niels Steensens vej 6, DK-2820, Gentofte, Denmark.
Curr Opin Investig Drugs. 2010 Apr;11(4):417-25.
Although the reconstitution of a functional beta-cell mass by transplantation of isolated islets can restore euglycemia in the absence of insulin treatment, a shortage of donor material is one of the factors preventing the general use of cell replacement therapy for the treatment of type 1 diabetes mellitus (T1DM). Advances in the directed differentiation of pluripotent stem cells toward beta-cells via the stepwise recapitulation of embryonic development have generated proof of concept demonstrating that stem cells may be an appropriate source of cells for the generation of therapeutic beta-cells. However, progress toward a clinical application of this technology is slow and challenging. This review highlights some of the critical issues impeding the translation of stem cell-based diabetes therapies to the clinic.
尽管通过移植分离的胰岛来重建功能性β细胞团能够在不进行胰岛素治疗的情况下恢复正常血糖，但供体材料短缺是阻碍细胞替代疗法广泛用于治疗1型糖尿病（T1DM）的因素之一。通过逐步重现胚胎发育过程，将多能干细胞定向分化为β细胞的研究取得了进展，已产生概念验证，表明干细胞可能是生成治疗性β细胞的合适细胞来源。然而，这项技术在临床应用方面进展缓慢且面临挑战。本综述重点介绍了一些阻碍基于干细胞的糖尿病治疗方法转化为临床应用的关键问题。
